Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis

American Journal of Gastroenterology

Volumn 102, Issue 10, 2007, Pages 2196-2205

  Sterling, Richard K ^a   Jeffers, Lennox ^b   Gordon, Fredric ^c   Sherman, Morris ^d   Venook, Alan P ^e   Reddy, K Rajender ^f   Satomura, Shinji ^g   Schwartz, Myron E ^h  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g FUJIFILM Wako Pure Chemical Corporation   (Japan)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; FEMALE; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; INCIDENCE; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE; PRIORITY JOURNAL; ULTRASOUND;

ADULT; AGED; ALPHA-FETOPROTEINS; CANADA; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DOUBLE-BLIND METHOD; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; UNITED STATES;

EID: 34848886470     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01405.x     Document Type: Article

References (55)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden GLOBOCAN 2000. Int J Cancer 2001 94 : 153 6.
2. El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004 127 : S27 34.
3. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000 160 : 3227 30.
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705 14.
5. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis. Gastroenterology 2006 130 : 231 64.
6. Shinagawa T, Ohto M, Kimura K, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. Gastroenterology 1984 86 : 495 502.
7. Ikeda K, Saitoh S, Koida I, et al. Diagnosis and follow-up of small hepatocellular carcinoma with selective intra-arterial digital subtraction angiography. Hepatology 1993 17 : 1003 7.
8. Oka H, Tamori A, Kuroki T, et al. Prospective study of a-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994 19 : 61 6.
9. Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinoma: Efficacy of various imaging procedures in 100 patients. AJR Am J Roentgenol 1990 155 : 49 54.
10. Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: Sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 1995 164 : 885 90.
11. Ebara M, Ohto M, Watanabe Y, et al. Diagnosis of small hepatocellular carcinoma: Correlation of MR imaging and tumor histological studies. Radiology 1986 159 : 371 7.
12. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: Review of experimental and clinical data. Cancer Res 1968 28 : 1344 50.
13. O'Connor GI, Tatarinov YS, Abelev GI, et al. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 1970 25 : 1091 8.
14. Biscegile AMD, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989 64 : 2117 20.
15. Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986 6 : 133 7.
16. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998 93 : 2452 6.
17. Goldstein NS, Blue DE, Hankin R, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999 111 : 811 6.
18. Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001 32 : 240 4.
19. Bisceglie AMD, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 2005 43 : 434 41.
20. Taketa K, Sekiya C, Namiki M, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990 99 : 508 18.
21. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive a-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993 53 : 5419 23.
22. Oka H, Saito A, Ito K, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive a-fetoprotein. J Gastroenterol Hepatol 2001 16 : 1378 83.
23. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993 328 : 1802 6.
24. Shiraki K, Takase K, Tameda Y, et al. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995 22 : 802 7.
25. Yamashita F, Tanaka M, Satomura S, et al. Monitoring of lectin-reactive a-fetoprotein in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 1995 7 : 627 33.
26. Yamashita F, Tanaka M, Satomura S, et al. Prognostic significance of Lens culinaris agglutinin A-reactive a-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996 111 : 996 1001.
27. Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of a-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999 94 : 3028 33.
28. Kumada T, Nakano S, Takeda I, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: Special reference to imaging diagnosis. J Hepatol 1999 30 : 125 30.
29. Tanaka M, Saito A, Ito K, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) is the most significant prognostic factor for hepatocellular carcinoma after therapy. Hepatology 2000 34 : 233 A.
30. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 30.
31. Katoh H, Nakamura K, Tanaka T, et al. Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem 1998 70 : 2110 4.
32. Yamagata Y, Katoh H, Nakamura K, et al. Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J Immunol Methods 1998 212 : 161 8.
33. Yamagata Y, Shimizu K, Nakamura K, et al. Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer. Clin Chim Acta 2003 327 : 59 67.
34. Bruix J SMPGC, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 36.
35. Sheu JC, Sung JL, Chen DS, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985 56 : 660 6.
36. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003 139 : 46 50.
37. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004 127 : S113 9.
38. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005 19 : 91 9.
39. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006 101 : 2051 9.
40. Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 2005 11 : 3205 9.
41. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxy prothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003 37 : 1114 21.
42. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma varies according to tumor size. Am J Gastroenterol 2006 101 : 2038 43.
43. Li D, Mallory T, Satomura S. AFP-L3: A new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001 313 : 15 9.
44. Moriwaki H, Yasuda I, Shiratori Y, et al. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997 3 : 727 31.
45. Fukuda H. Tumor vascularity and Lens culinaris agglutinin reactive alpha-fetoprotein are predictors of long-term prognosis in patients with hepatocellular carcinoma after percutaneous ethanol injection therapy. Kurume Med J 1998 45 : 187 93.
46. Aoyagi Y, Isokawa O, Suda T, et al. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 1998 83 : 2076 82.
47. Kusaba T. Relationship between Lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma. Kurume Med J 1998 45 : 113 20.
48. Yamashiki N, Seki T, Wakabayashi M, et al. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep 1999 6 : 1229 32.
49. Taketa K, Okada S, Win N, et al. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama 2002 56 : 317 20.
50. Khien VV, Mao HV, Chinh TT, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001 16 : 105 11.
51. Yoshida S, Kurokohchi K, Arima K, et al. Clinical significance of Lens culinaris agglutin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002 20 : 305 9.
52. Wang SS, Lu RH, Lee FY, et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996 25 : 166 71.
53. Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006 4 : 111 7.
54. Ikeda K, Arase Y, Saitoh S, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol 2006 44 : 1089 97.
55. Leerapun A, Suravarapu SV, Bida JP, et al. The utility of Lens culinaris agglutinin-reative α-fetoprotein in the diagnsis of hepatocellular carcinoma: Evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007 5 : 394 402.